The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn.

Abstract

OBJECTIVE:

Characterize association between hydrocortisone receipt and hospital outcomes of infants with persistent pulmonary hypertension of the newborn (PPHN).

STUDY DESIGN:

Cohort study of infants ≥34 weeks with PPHN who received inhaled nitric oxide at <7 days of age (2010-2016). We generated propensity scores, and performed inverse probability-weighted regression to estimate hydrocortisone effect on outcomes: death, chronic lung disease (CLD), oxygen at discharge.

RESULTS:

Of 2743 infants, 30% received hydrocortisone, which was associated with exposure to mechanical ventilation, sedatives, paralytics, or vasopressors (p < 0.001). There was no difference in death, CLD, or oxygen at discharge. In infants with meconium aspiration syndrome, hydrocortisone was associated with decreased oxygen at discharge (odds ratio 0.56; 95% confidence interval 0.21, 0.91).

CONCLUSIONS:

There was no association between hydrocortisone receipt and death, CLD, or oxygen at discharge in our cohort. Prospective studies are needed to evaluate the effectiveness of hydrocortisone in infants with PPHN.

• Authors: Samia Aleem, Cliff Robbins, Brianna Murphy, Stephen Elliott, Christiana Akinyemi, Nicholas Paredes, Veeral N Tolia, Kanecia O Zimmerman, Ronald N Goldberg, Daniel K Benjamin, Rachel G Greenberg
• Journal: Journal of perinatology : official journal of the California Perinatal Association (J Perinatol) Vol. 41 Issue 4 Pg. 794-800 (04 2021) ISSN: 1476-5543 [Electronic] United States
• PMID: 33589734 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Nitric Oxide
• Hydrocortisone

Topics

• Administration, Inhalation
• Cohort Studies
• Humans
• Hydrocortisone (therapeutic use)
• Hypertension, Pulmonary (drug therapy)
• Infant
• Infant, Newborn
• Meconium Aspiration Syndrome
• Nitric Oxide (therapeutic use)
• Persistent Fetal Circulation Syndrome (drug therapy)